NEWSROOM

NASDAQ

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024

PITTSBURGH, Oct. 09, 2024 - PRISM MediaWire - Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024. Event: Lipella Presentation - 2024 Maxim Healthcare Virtual Summit Date: Thursday, October 17th, 2024...

SKYX Provides Corporate Update, including Significant Insider Buying

SKYX Provides Corporate Update, including Significant Insider Buying

Oct 9, 2024

MIAMI, Oct. 09, 2024 - PRISM MediaWire - SKYX (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive smart platform technology company with over 97 issued and pending patents in the U.S. and globally, and which owns over 60 lighting and home décor websites with a mission to make homes and buildings become smart, safe, and advanced as the new standard, provides today a corporate update including significant insider buying. SKYX Secures $11 million equity preferred stock investment...

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Oct 8, 2024

Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., October 8, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test,...

Sono-Tek Announces Fiscal Second Quarter and First Half 2025 Earnings Conference Call

Sono-Tek Announces Fiscal Second Quarter and First Half 2025 Earnings Conference Call

Oct 8, 2024

Conference Call on Tuesday, October 15, 2024 at 10:00 am ET MILTON, NY, October 8, 2024 – PRISM MediaWire - Sono-Tek Corporation (NASDAQ: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that the Company will hold a conference call to discuss its fiscal second quarter and first half 2025 financial results, ended August 31, 2024, on Tuesday, October 15, 2024 at 10:00 am ET. The second quarter and first half FY 2025 financial results press release will...

SKYX Provides Corporate Update, including Significant Insider Buying

SKYX Secures $11 Million Strategic Investment at $2.00 Per Share, Preferred Stock Convertible, Led by Global Marriott Hotel-Chain Developer, Lance Shaner, Owner of over 60 Hotels, Primarily Marriotts

Oct 7, 2024

Management Emphasizes That It Has Sufficient Cash to Achieve Its Goals Including Recently Announced Collaborations and Being Cash Flow Positive During 2025 The $11 Million Investment includes Leading Builders and Hotel Developers MIAMI, October 07, 2024 - PRISM MediaWire - SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the "Company" or "SKYX"), a highly disruptive smart platform technology company with more than 97 issued and pending patents globally and over 60 lighting and...

AmpliTech Group Announces Receipt of Notice of Allowance for Patents in 5G and Cryogenic Technology For Quantum Computing Applications

AmpliTech Group Announces Receipt of Notice of Allowance for Patents in 5G and Cryogenic Technology For Quantum Computing Applications

Oct 7, 2024

Hauppauge, NY, October 7, 2024 – PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of...

Oncocyte Signs Leading Transplant Centers in US and Germany

Oncocyte Signs Leading Transplant Centers in US and Germany

Oct 2, 2024

GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volume Company clears first stage gate in clinical product development process and has submitted a Q-Sub to the FDA IRVINE, Calif., Oct. 02, 2024 - PRISM MediaWire - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany. Both...

Oncocyte Signs Leading Transplant Centers in US and Germany

Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Oct 2, 2024

Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc., one of the Company’s strategic partners. The gross proceeds to the Company from the...

AmpliTech Group Announces Receipt of Notice of Allowance for Patents in 5G and Cryogenic Technology For Quantum Computing Applications

AmpliTech Group Received Nasdaq Notification of Non-Compliance with Listing Rules 5550(a)(2)

Sep 30, 2024

Company Expects To Regain Compliance Within Specified Period HAUPPAUGE, N.Y., Sept. 30, 2024 - PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW) (the “Company”), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, received a notice (the “Notice”)...

BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting

BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting

Sep 30, 2024

Nasdaq listing aims to increase market visibility and global liquidity opportunities as BioStem advances its commercial and clinical initiatives amid record revenue growth Pompano Beach, FL, September 30, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading MedTech company focused on the development, manufacture and commercialization of placental-derived biologics, announces the filing of a Form 10 registration statement (the “Registration...

Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)

Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)

Sep 30, 2024

Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development New York, NY, September 30, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific...

LuxUrban Hotels Inc. Reports Second Quarter 2024 Financial Results

LuxUrban Hotels Inc. Reports Second Quarter 2024 Financial Results

Sep 25, 2024

Miami, Florida, September 25, 2024 – PRISM MediaWire - LuxUrban Hotels Inc. (Nasdaq: LUXH), a hospitality company that leases entire hotels on a long-term basis, manages these hotels, and rents out rooms to guests in the properties it leases, today announced its financial results for the second quarter ended June 30, 2024 (“Q2 2024”). The Company has also submitted its quarterly report on Form 10-Q to the U.S. Securities and Exchange Commission. Q2 2024 Financial Overview: Net Rental Revenue:...

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

Sep 25, 2024

NEW YORK, September 25, 2024 - PRISM MediaWire - PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO). In this interview, Dr. Chancellor provides insights into the company's latest advancements in urological treatments, particularly in recognition of Urology Awareness Month, and discusses the significant progress made in the development of therapies for hemorrhagic cystitis (HC)....

LuxUrban Hotels to Host Webcast to Review the Financial Results for the Second Quarter of 2024

LuxUrban Hotels to Host Webcast to Review the Financial Results for the Second Quarter of 2024

Sep 25, 2024

Conference Call and Webcast to be held on September 25, 2024 at 5:00 PM ET MIAMI, Florida, September 25, 2024 - PRISM MediaWire - LuxUrban Hotels Inc. (“LuxUrban” or the “Company”) (Nasdaq: LUXH), which secures long-term operating rights for entire hotels through Master Lease Agreements (MLA) under which it manages the hotel and rents out, on a short-term basis, rooms to business and vacation travelers, will host a webcast to review the results of the 2nd quarter of 2024 on...

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

Sep 24, 2024

PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). The Company reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with...

AmpliTech Group Receives Over $700,000 In Cash From Single Products Sale At Their Spectrum Division

AmpliTech Group Receives Over $700,000 In Cash From Single Products Sale At Their Spectrum Division

Sep 19, 2024

September Bookings To Date Also Surpassed $1 Million Mark Hauppauge, NY, September 19, 2024 - PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced receipt of the single cash payment,...

ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.

ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.

Sep 17, 2024

Strategic Rebranding Reflects Focus on Neurodegenerative Therapies and Healthy Longevity New York, NY, September 17, 2024 - PRISM MediaWire - The Board of ANEW MEDICAL, INC. (NASDAQ: WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ: KLTO), and has launched a new website, www.klothoneuro.com. The name and ticker change will have no impact on current shareholders, and there is no action required on their part. The new name embodies the Company's...

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 13, 2024

NEW YORK, September 13, 2024 - PRISM MediaWire - PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON). As a disruptive healthcare technology company focused on chronic low back pain, Aclarion is at the forefront of developing noninvasive tools to help physicians identify the source of pain in spinal discs, potentially revolutionizing the standard of care for this widespread and debilitating condition. Aclarion's Nociscan platform,...

AmpliTech Group Receives Over $700,000 In Cash From Single Products Sale At Their Spectrum Division

AmpliTech Group’s AGTGSS Division Receives Initial Order For Its Midband 5G Radio Networks From Historic University of Edinburgh UK

Sep 12, 2024

Hauppauge, NY, September 12, 2024 – PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced receiving a purchase order for its midband 5G radio networks from Historic University of...

AmpliTech Group Announces Receipt of Notice of Allowance for Patents in 5G and Cryogenic Technology For Quantum Computing Applications

AmpliTech Group Announces Pricing of $1.0 Million Registered Direct Offering, Priced At-The-Market

Sep 9, 2024

HAUPPAUGE, N.Y., Sept. 9, 2024 - PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW) (the “Company”), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced that it has entered into a securities purchase agreement with a single...

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Aclarion Added to PRISM Emerging Medical Devices Index

Sep 6, 2024

Company's industry-first technology addresses chronic low back pain Aclarion secured its first commercial agreement with Michigan's Sheridan Community Hospital PRISM Emerging Medical Devices Index features companies at forefront of innovation and market disruption in medtech NEW YORK, September 06, 2024 – PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index,...

AmpliTech Group’s AGTGSS Division To Participate At Mobile World Congress Shows in Las Vegas And Barcelona To Market Its Comprehensive Private 5G End-to-End Solution for Businesses and Homes

Sep 4, 2024

This includes External and Internal CPE and Fixed 5G Wireless Access (FWA) equipment Hauppauge, NY, September 4, 2024 – PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, announces the company’s...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

Sep 4, 2024

Company will use novel, patented Klotho Gene (s-KL) in studies New York, NY, September 4, 2024 - PRISM MediaWire - ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer’s and...

AmpliTech Group Receives Over $700,000 In Cash From Single Products Sale At Their Spectrum Division

AmpliTech Group’s Bookings Surpass $1M In August 2024

Aug 30, 2024

In Addition To Above Bookings, Spectrum Semiconductor Materials Division Completes $700K Single Sale Transaction During The Week of August 26th 2024 Hauppauge, NY, August 30, 2024 – PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and...

BranchOut Food Delivers Shareholder Update: 2024 Revenue Surges 640% in First Half, Poised for Continued Growth and Debt Elimination by Q4 2025

BranchOut Food Delivers Shareholder Update: 2024 Revenue Surges 640% in First Half, Poised for Continued Growth and Debt Elimination by Q4 2025

Aug 28, 2024

BranchOut Food estimated to finish year at $8 million in Net Revenue Net Revenue for 1st half 2024 up over 640% from revenue in 1st half 2023 The Company estimates $5 million in Revenue for 2nd half of 2024, double that of the same period last year, to finish 2024 near $8 million Opening new production facility in Peru with about $40 mm in capacity with first production anticipated in October Completed combined financing of $5.4 million in June and July 2024 to finance completion of new...

Lipella Pharmaceuticals to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York

Lipella Pharmaceuticals to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York

Aug 27, 2024

Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway Pittsburgh, PA, August 27, 2024 – Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York City at the Lotte New York Palace Hotel on September 9 through 11, 2024. Admission to H.C. Wainwright’s conference is for qualified investors, and Lipella will be giving a virtual...

AmpliTech Group Receives Over $700,000 In Cash From Single Products Sale At Their Spectrum Division

AmpliTech Group’s AGMDC Division Moves to Allen Tech Hub in Watters Creek District in Allen, Texas

Aug 26, 2024

Hauppauge, NY, August 26, 2024 – AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced its AmpliTech Group Microwave Design Center move into the prestigious cutting-edge Allen Tech Hub in the heart of...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility

Aug 26, 2024

Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW’s balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in...

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Aug 22, 2024

Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth No FDA-approved therapy currently exists for OLP Patient registry and OLP study information is now available Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory...

Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy

ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)

Aug 21, 2024

New York, NY. August 21, 2024 - ANEW MEDICAL, INC. (“ANEW” or the “Company”) (NASDAQ: WENA), announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke(“TTS”)regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have...